12:29 PM EDT, 07/09/2024 (MT Newswires) -- Soligenix ( SNGX ) shares skyrocketed more than 400% in recent Tuesday trading after the company reported positive results of a study evaluating extended HyBryte treatment in patients with early-stage cutaneous T-cell lymphoma.

The company said six patients were enrolled in the Phase 3 FLASH study and treated with HyBryte over a period of up to 44 weeks, and they responded positively to the therapy with 75% achieving "treatment success."

Two of the three "treatment successes" were achieved within the first 12 weeks of treatment and one within 18 weeks, it said.

HyBryte appears to be safe and well tolerated in all patients, with no treatment-related adverse events reported to date, the firm said. The study was supported by $2.6 Million FDA Orphan Products Development Grant.

Price: 10.10, Change: +8.10, Percent Change: +404.85